Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141581 · ClinicalTrials.gov registry record · Phase 4
Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)
A Phase 4 study of Influenza, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 86
- Enrollment target
- 1
- Study location
NCT02141581 is a Phase 4 study of Influenza that has completed, run by Stanford University. The registered enrollment target is 86 participants, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02141581, a Phase 4 study of Influenza, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 86 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the responses to licensed trivalent, inactivated influenza vaccine (TIV) delivered by different routes: intramuscular (IM) and intradermal (ID) and to the live, attenuated influenza vaccine (LAIV) administered intranasally -- all given to generally healthy male and female adult volunteers.
Conditions Studied
Interventions
- BIOLOGICAL Fluzone® (IM)
- BIOLOGICAL Fluzone® Intradermal (ID)
- BIOLOGICAL 2011-2012 FluMist®
Study Locations (1)
California
- Stanford LPCH Vaccine Program - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02141581
The ClinicalTrials.gov registry entry for NCT02141581 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 3 interventions - of which Fluzone® (IM) is the first listed.
NCT02141581 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02141581 about?
NCT02141581 is a clinical study titled "Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)". The purpose of this study is to investigate the responses to licensed trivalent, inactivated influenza vaccine (TIV) delivered by different routes: intramuscular (IM) and intradermal (ID) and to the live, attenuated influenza vaccine (LAIV) administered intranasally -- all given to generally healthy...
What is the current status of trial NCT02141581?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 86 participants. The study started on 2011-08. Estimated completion is 2014-12.
What conditions does trial NCT02141581 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT02141581?
The interventions under investigation include: Fluzone® (IM) (BIOLOGICAL), Fluzone® Intradermal (ID) (BIOLOGICAL), 2011-2012 FluMist® (BIOLOGICAL).
Who is sponsoring clinical trial NCT02141581?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02141581 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
Bone Marrow and Peripheral Blood Immune Responses Study
RECRUITING · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
COMPLETED · Phase 4
-
A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age
COMPLETED · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.